Category - Markets

Markets

RJ starts WELL Health at OP; PT $8.50 (Canadian)

Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...

April 28, 2023

Markets

Cantor starts Disc Medicine at OW; PT $45

Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...

April 28, 2023

Markets

Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth...

April 27, 2023

Markets

Stifel ups IDEAYA to buy; PT to $24 on increased conviction of darovasertib

Stifel upgraded IDEADYA Biosciences (NASDAQ:IDYA) to “buy” from “hold” and raised its price target to $24 from $18 following additional darovasertib data in uveal melanoma, which revealed an improved mPFS in first-line...

April 24, 2023

Markets

Stifel starts Disc Medicine at buy; PT $37

Stifel launched coverage of Disc Medicine (NASDAQ:IRON) with a “buy” rating and $37 price target. The stock closed at $28.10, up $2.34, on April 20. “Our positive thesis is predicated on optimism for the company’s lead...

April 21, 2023

Markets

WB starts CymaBay at OP citing de-risked late-stage asset

William Blair launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating. The stock closed at $8.66 on April 3. CymaBay is advancing seladelpar, a selective peroxisome proliferator-activated...

April 5, 2023

Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023

Markets

WB starts MDxHealth at outperform

William Blair launched coverage of MDxHealth S.A. (NASDAQ:MDXH) with an “outperform” rating. The stock closed at $2.86 on March 23. Analyst Andrew Brackmann writes that the rating is based on his belief that the company...

March 24, 2023

Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023

Markets

Stifel starts Theseus Pharma at buy; PT $24

Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...

March 16, 2023

Category - Markets

Subscribe